Medical treatment of patients with intracranial atherosclerotic disease

Journal of Neuroimaging

Volumn 19, Issue SUPPL. 1, 2009, Pages

  Gomez, Camilo R ^a   Qureshi, Adnan I ^b  

^a Alabama Neurological Institute   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aspirin; Aspirin dipyrimadole; Clopidogrel; Intracranial atherosclerosis; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY OCCLUSION; BLEEDING; BRAIN ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG FATALITY; DRUG SAFETY; DYNAMICS; EMBOLISM; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; PILOT STUDY; PRACTICE GUIDELINE; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ASPIRIN; ATHEROSCLEROSIS; BRAIN ISCHEMIA; DIPYRIDAMOLE; EMBOLISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACRANIAL ARTERIOSCLEROSIS; INTRACRANIAL THROMBOSIS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TETRAZOLES; TICLOPIDINE;

EID: 70350513170     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2009.00419.x     Document Type: Review

References (23)

1. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005 352 : 1305 1316.
2. Wong KS, Chen C, Ng PW, et al. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007 6 : 407 413.
3. Grotta JC, Norris JW, Kamm B. Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. Neurology 1992 42 : 111 115.
4. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003 289 : 2947 2957.
5. Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006 367 : 1665 1673.
6. Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007 6 : 115 124.
7. Kremer C, Schaettin T, Georgiadis D, et al. Prognosis of asymptomatic stenosis of the middle cerebral artery. J Neurol Neurosurg Psychiatry 2004 75 : 1300 1303.
8. Nahab F, Cotsonis G, Lynn M, et al. Prevalence and prognosis of coexistent asymptomatic intracranial stenosis. Stroke 2008 39 : 1039 1041.
9. Harrington RA, Armstrong PW, Graffagnino C, et al. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000 102 : 728 735.
10. Adams RJ, Albers G, Alberts MJ, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008 39 : 1647 1652.
11. Ibanez B, Vilahur G, Badimon JJ. Plaque progression and regression in atherothrombosis. J Thromb Haemostas 2007 5 (Suppl 1 292 299.
12. Lee JMS, Choudhury RP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart 2007 93 : 559 564.
13. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005 36 : 782 786.
14. Bae J-H, Rihal CS, Edwards BS, et al. Association of angiotensin- converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 2006 82 : 1108 1111.
15. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Therapeut 2003 99 : 95 112.
16. Kushner PR. Can intensive statin therapy halt the progression of atherosclerosis? Recent evidence and potential implications for patient management. Prog Cardiovasc Nurs 2007 22 : 207 213.
17. Chaturvedi S, Turan TN, Lynn MJ, et al. Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 2007 69 : 2063 2068.
18. Ovbiagele B, Saver JL, Lynn MJ, et al. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology 2006 66 : 1344 1349.
19. Turan TN, Cotsonis G, Lynn MJ, et al. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation 2007 115 : 2969 2975.
20. Amarenco P, Bogousslavsky J, Callahan A, 3rd., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 355 : 549 559.
21. Amarenco P, Bogousslavsky J, Callahan AS, et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 2003 16 : 389 395.
22. Goldstein LB, Amarenco P, Lamonte M, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008 39 : 2444 2448.
23. Adams RJ, Chimowitz MI, Alpert JS, et al., the Council on Clinical Cardiology of the American Heart A, American Stroke A. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003 108 : 1278 1290.